Dupilumab Therapy for EGIDs
Recruiting now
Conditions studied: Eosinophilic Gastrointestinal Disorders (EGIDs)
In brief
This is a single-center observational study to investigate the efficacy and tolerability of dupilumab in children with refractory eosinophilic gastrointestinal disorders.
Key facts
- Study ID
- NCT07257835
- Run by
- Children's Hospital of Fudan University
- People needed
- 20
- Starts
- 2025-01-01
- Expected to finish
- 2027-12-01
- Last updated by the study team
- 2025-12-02
Who can join
Age: 1 and older, up to 18. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Clinical diagnosis of Refractory Peptic Ulcers
- with Refractory Eosinophilic Gastrointestinal Disorders
You may not qualify if…
- with Active Helicobacter pylori infection at present.
- with Inflammatory bowel disease
- with Parasite infection
- with Cancer
Where it is running
- 201102 — Shanghai, China (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.